It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block
specific cytokine pathways has revealed pathophysiological differences among autoimmune …

Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …

Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …

Genome-wide association studies (GWAS) have revealed important biological insights into
complex diseases, which are broadly expected to lead to the identification of new drug …

Pathophysiology of Inflammatory Bowel Diseases Research on IBDs has identified disrupted
immune responses in the gastrointestinal mucosa and putative disruptions in the gut …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …